Breast Cancer Clinical Trial
IFACT: Incidental Findings in Advanced Cancer Therapy
Summary
The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.
Full Description
Part 1, the investigators will recruit 40 participants from those already enrolled in existing MSK IRB protocol #12-245 (PI: David Hyman, MD) including male and female patients who have been diagnosed with late-stage breast, colorectal, bladder, and lung cancer (some of the most common cancers in this study population).
Part 2, the investigators will recruit 20 participants from those who have actually received incidental germline findings from MSK IRB protocol #12-245 Consent Part C in order to cognitively test novel survey items about their knowledge and perceived utility of their incidental findings (note that the content of these items will be derived from the data collected in Part 1)
Eligibility Criteria
Inclusion Criteria:
Part 1:
Patient enrolled on MSK protocol #12-245
Living patient age 18 or older
Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area
Part 2:
Living patient age 18 or older
Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant
Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area
Exclusion Criteria for Part 1 and 2:
Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages.
Patient unwilling or unable to provide informed consent.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?